Corrigendum
December 2022
in “
Journal of The European Academy of Dermatology and Venereology
”
TLDR The 7.1% withdrawal rate was in the oral finasteride group, not the topical one.
In the article by B.M. Piraccini et al., there was an error in the "Safety assessment" subsection. The incorrect sentence stated that withdrawal rates due to treatment-related TEAEs were 2.8% and 2.2% in the topical finasteride and placebo groups, respectively, and 7.1% in the topical finasteride group. The corrected sentence clarifies that the 7.1% withdrawal rate was actually in the oral finasteride group.